Recent Quotes

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

Axsome Therapeutics, Inc. - Common Stock (NQ:AXSM)

241.12 -0.55 (-0.23%)

Streaming Delayed Price Updated: 4:00 PM EDT, Jun 29, 2026 Add to My Watchlist

Price and Volume

Detailed Quote

Volume	1,338,068
Open	244.08
Bid (Size)	236.50 (200)
Ask (Size)	241.90 (100)
Prev. Close	241.67
Today's Range	236.47 - 248.15
52wk Range	96.09 - 260.19
Shares Outstanding	47,190,970
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

Axsome Therapeutics Initiates FOCUS-3 Phase 3 Trial of Solriamfetol in Adolescents with Attention Deficit Hyperactivity Disorder (ADHD)

June 26, 2026

From Axsome Therapeutics, Inc.

Via GlobeNewswire

Axsome Therapeutics Highlights the Importance of Brain Health During Alzheimer's & Brain Awareness Month

June 18, 2026

From Axsome Therapeutics, Inc.

Via GlobeNewswire

Performance

YTD	+34.9%	+34.9%
1 Month	+2.8%	+2.8%
3 Month	+50.2%	+50.2%
6 Month	+60.0%	+60.0%
1 Year	+131.0%	+131.0%

More News

3 Under-the-Radar Stocks to Buy and Hold for a Decade ↗

June 16, 2026

Via The Motley Fool

Axsome Therapeutics Presents New Data Highlighting its Innovative Sleep Medicine Portfolio at SLEEP 2026

June 15, 2026

From Axsome Therapeutics, Inc.

Via GlobeNewswire

Axsome Therapeutics (NASDAQ:AXSM) Q1 Revenue Beat Misses Estimates as Launch Costs Surge ↗

May 04, 2026

Via Chartmill

Axsome Therapeutics Readies Auvelity Alzheimer’s Agitation Launch, Expands CNS Pipeline ↗

June 06, 2026

Via MarketBeat

Axsome Therapeutics Presents New SYMBRAVO® Data at the Americal Headache Society (AHS) 68th Annual Scientific Meeting

June 04, 2026

From Axsome Therapeutics, Inc.

Via GlobeNewswire

Axsome Therapeutics Announces Settlement Resolving All SUNOSI® (solriamfetol) Patent Litigation

June 03, 2026

From Axsome Therapeutics, Inc.

Via GlobeNewswire

Axsome Therapeutics Partners with the Headache Alliance to Highlight the Impact of Migraine During Migraine and Headache Awareness Month

June 01, 2026

From Axsome Therapeutics, Inc.

Via GlobeNewswire

Axsome Therapeutics to Participate in Upcoming Investor Conferences

May 27, 2026

From Axsome Therapeutics, Inc.

Via GlobeNewswire

Axsome Therapeutics Presents New AUVELITY® Data in Major Depressive Disorder at the American Society of Clinical Psychopharmacology (ASCP) 2026 Annual Meeting

May 26, 2026

From Axsome Therapeutics, Inc.

Via GlobeNewswire

This Biotech Is Up 60%. A Top Healthcare Fund Just Bought Another $11 Million ↗

May 24, 2026

Via The Motley Fool

Axsome Therapeutics Bets on AUVELITY Expansion With June Alzheimer’s Agitation Launch ↗

May 12, 2026

Via MarketBeat

3 Stocks Poised to Disrupt the Healthcare Market by 2030 ↗

May 08, 2026

Via The Motley Fool

Axsome Therapeutics Recognizes Mental Health Month

May 07, 2026

From Axsome Therapeutics, Inc.

Via GlobeNewswire

3 Overlooked Stocks Set to Soar in 2026 ↗

May 05, 2026

Via The Motley Fool

Axsome Therapeutics to Participate in Upcoming Investor Conferences

May 05, 2026

From Axsome Therapeutics, Inc.

Via GlobeNewswire

Why Did Axsome Therapeutics Stock Hit Another Record High Today? ↗

May 04, 2026

Via The Motley Fool

Axsome (AXSM) Q1 2026 Earnings Call Transcript ↗

May 04, 2026

Via The Motley Fool

Axsome (AXSM) Q2 2025 Earnings Transcript ↗

May 04, 2026

Via The Motley Fool

Axsome (AXSM) Q1 2025 Earnings Call Transcript ↗

May 04, 2026

Via The Motley Fool

Axsome Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update

May 04, 2026

From Axsome Therapeutics, Inc.

Via GlobeNewswire

Why Axsome Therapeutics Stock Jumped Over 20% in April ↗

May 02, 2026

Via The Motley Fool

Axsome Therapeutics Hosts AUVELITY® FDA Approval Investor Event Featuring Expert Thought Leader

May 01, 2026

From Axsome Therapeutics, Inc.

Via GlobeNewswire

Axsome Therapeutics Announces FDA Approval of AUVELITY® (dextromethorphan HBr and bupropion HCl) for the Treatment of Agitation Associated with Dementia due to Alzheimer’s Disease

April 30, 2026

From Axsome Therapeutics, Inc.

Via GlobeNewswire

Frequently Asked Questions

Is Axsome Therapeutics, Inc. - Common Stock publicly traded?

Yes, Axsome Therapeutics, Inc. - Common Stock is publicly traded.

What exchange does Axsome Therapeutics, Inc. - Common Stock trade on?

Axsome Therapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market

What is the ticker symbol for Axsome Therapeutics, Inc. - Common Stock?

The ticker symbol for Axsome Therapeutics, Inc. - Common Stock is AXSM on the Nasdaq Stock Market

What is the current price of Axsome Therapeutics, Inc. - Common Stock?

The current price of Axsome Therapeutics, Inc. - Common Stock is 241.12

When was Axsome Therapeutics, Inc. - Common Stock last traded?

The last trade of Axsome Therapeutics, Inc. - Common Stock was at 06/29/26 04:00 PM ET

What is the market capitalization of Axsome Therapeutics, Inc. - Common Stock?

The market capitalization of Axsome Therapeutics, Inc. - Common Stock is 11.38B

How many shares of Axsome Therapeutics, Inc. - Common Stock are outstanding?

Axsome Therapeutics, Inc. - Common Stock has 11B shares outstanding.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.